Results 51 to 60 of about 4,313 (158)

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III Trial

Allergy, EarlyView.
Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian, Menglin Wang, Changqing Zhao, Lijia Wan, Yu Xu, Juan Meng, Rui Xu, Xicheng Song, Li Shi, Yucheng Yang, Yan Jiang, Yanzhen Wu, Bethany Ling, Vivian Li, Andrew P. Fontenot, Lacey R. Robinson, Neelam A. Phadke, Chengshuo Wang, Luo Zhang   +18 more
wiley   +1 more source

Clinical Images: Angiolymphoid hyperplasia with eosinophilia mimicking Temporal Arteritis

Arthritis &Rheumatology, EarlyView.
Jonas Menz, Konstanze Holl‐Ulrich, Lukas Brachaczek, Gabriela Riemekasten, Peter Lamprecht   +4 more
wiley   +1 more source

Mepolizumab Modifies Blood Eosinophil Proteome and Transcriptome in Severe Eosinophilic Asthma

Allergy, EarlyView.
This study investigates the effect of mepolizumab on the proteomic and transcriptomic profile of blood eosinophils in SEA patients. Mepolizumab reduces the migratory capacity and effector‐related molecular signatures of circulating eosinophils in SEA patients.
Pablo Miguéns‐Suárez, Sara Vázquez‐Mera, Laura Martelo‐Vidal, Marina Blanco Aparicio, Uxío Calvo Álvarez, Coral González Fernández, Mar Mosteiro Añón, Dolores Corbacho Abelaira, Tamara Hermida Valverde, Christian Calvo Henríquez, Susana B. Bravo, Lena Uller, Juan J. Nieto‐Fontarigo, Francisco J. Salgado, Francisco J. González‐Barcala   +14 more
wiley   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Diagnostic Delay in Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors and Implications for Earlier Recognition

Allergy, EarlyView.
This study aimed to assess diagnostic delay among patients with eosinophilic granulomatosis with polyangiitis (EGPA) and identify clinical characteristics associated with delayed recognition. EGPA diagnosis was delayed by nearly five years from symptom onset in this single‐center cohort.
Vani Mulkareddy, Kalena Liu, Shreya Mandloi, Kelsey Limage, Samuel R. Shing, Gurston G. Nyquist, Jessica Most, David Kennedy, Elina Toskala, Damaris Pena‐Evertz   +9 more
wiley   +1 more source

A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma

Clinical &Experimental Allergy, EarlyView.
Among patients with severe eosinophilic asthma, benralizumab was associated with greater improvements in asthma outcomes—such as improved asthma control, quality of life and remission rates—compared to biologic‐naïve patients. ABSTRACT Background Real‐world data on benralizumab in patients with severe eosinophilic asthma–while controlling for ...
Dennis Thomas, Vanessa M. McDonald, Gijo Thomas, Joy Lee, Li Ping Chung, Matthew Peters, Shakti D. Shukla, Yuto Hamada, Erin S. Harvey, Michael Fricker, Hayley See, Rejoy Sabin Thomas, Claude S. Farah, Andrew Gillman, Constance H. Katelaris, Gregory P. Katsoulotos, David Langton, Peter G. Middleton, Paul Reynolds, Janet Rimmer, Francis Thien, Stephen Vincent, John W. Upham, Peter G. Gibson   +23 more
wiley   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

European Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy

Immunology &Cell Biology, EarlyView.
IL‐12 levels are tightly regulated to balance effective protective immunity against infections and cancer with the risk of excessive inflammation and autoimmune disease. Both insufficient and excessive IL‐12 activity can therefore be detrimental, highlighting the importance of precisely controlling its production and signaling. ABSTRACT Interleukin‐12 (
Anthi Psoma, Geert van den Bogaart
wiley   +1 more source

Therapeutic potential of a Bax inhibitor‐1/TMBIM6 antagonist (BIA) and its analogues in Aspergillus fumigatus‐induced asthma via dual targeting of AKT and epithelial‐derived inflammatory cytokines

British Journal of Pharmacology, Volume 183, Issue 19, Page 5975-5991, October 2026.
Background and Purpose Aspergillus fumigatus (A. fumigatus) exposure causes of severe allergic asthma, characterized by airway inflammation and epithelial dysfunction. TMBIM6 (Bax inhibitor‐1) has been implicated in airway epithelial stress responses and AKT signalling.
Young‐Jin Yu, Ahsan Ullah, Jisun Kim, Mehedi Hasan Bappi, Yerim Heo, Jin Hee Ahn, Hyun‐Kyoung Kim, Han‐Jung Chae   +7 more
wiley   +1 more source

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies

European Journal of Clinical Investigation, Volume 56, Issue 10, October 2026.
COPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Sasha Raman, Sreya Rahman, Francesca Polverino, Muhammad Adrish   +3 more
wiley   +1 more source